Literature DB >> 8675694

Differential expression in glioblastoma multiforme and cerebral hemangioblastoma of cytoplasmic proteins that bind two different domains within the 3'-untranslated region of the human glucose transporter 1 (GLUT1) messenger RNA.

H Tsukamoto1, R J Boado, W M Pardridge.   

Abstract

The glucose transporter 1 (GLUT1) protein is underexpressed in human glioblastoma multiforme and is overexpressed in human cerebral hemangioblastoma. To gain in-sight into possible posttranscriptional mechanisms regulating the expression of the GLUT1 protein in human brain tumors, cytosolic proteins were prepared from these two tumors and used in RNase T1 protection assays that employed [32P]human GLUT1 synthetic RNA prepared from transcription plasmids. Gel shift mobility assays and ultra-violet light cross-linking studies demonstrated the formation of specific RNA/protein complexes that migrated with a mol mass of 120, 44, and 41 kD. RNase T1 mapping and oligodeoxynucleotide competition studies showed that the 120 kD complex was comprised of an RNA fragment that localized to nucleotides 2186-2203 of the GLUT1 mRNA. The 44 kD complex contained an adenosine-uridine-rich RNA fragment that localized to nucleotides 1885-1906 of the human GLUT1 mRNA, and the formation of this complex was inhibited by synthetic RNA enriched in adenosine-uridine sequences. The 44 kD complex was selectively downregulated in hemangioblastoma as compared to glioblastoma multiforme. These studies demonstrate that human brain tumors have differential regulation of cytosolic proteins that specifically interact with two different domains in the 3'-untranslated region of the GLUT1 mRNA, which may serve to mediate the posttranscriptional regulation of GLUT1 gene expression in these tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675694      PMCID: PMC507376          DOI: 10.1172/JCI118738

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  32 in total

1.  A novel transiently expressed, integral membrane protein linked to cell activation. Molecular cloning via the rapid degradation signal AUUUA.

Authors:  H W Gaugitsch; E E Prieschl; F Kalthoff; N E Huber; T Baumruker
Journal:  J Biol Chem       Date:  1992-06-05       Impact factor: 5.157

Review 2.  Metabolic stability of mRNA in yeast--a potential target for modulating productivity?

Authors:  H A Raué
Journal:  Trends Biotechnol       Date:  1994-11       Impact factor: 19.536

Review 3.  Conserved structures and diversity of functions of RNA-binding proteins.

Authors:  C G Burd; G Dreyfuss
Journal:  Science       Date:  1994-07-29       Impact factor: 47.728

4.  Distribution of the glucose transporters in human brain tumors.

Authors:  T Nishioka; Y Oda; Y Seino; T Yamamoto; N Inagaki; H Yano; H Imura; R Shigemoto; H Kikuchi
Journal:  Cancer Res       Date:  1992-07-15       Impact factor: 12.701

5.  Complete protection of antisense oligonucleotides against serum nuclease degradation by an avidin-biotin system.

Authors:  R J Boado; W M Pardridge
Journal:  Bioconjug Chem       Date:  1992 Nov-Dec       Impact factor: 4.774

6.  An estrogen-dependent polysomal protein binds to the 5' untranslated region of the chicken vitellogenin mRNA.

Authors:  H M Liang; J P Jost
Journal:  Nucleic Acids Res       Date:  1991-05-11       Impact factor: 16.971

7.  The erythrocyte-type glucose transporter in blood vessels of primary and metastatic brain tumors.

Authors:  S I Harik; U Roessmann
Journal:  Ann Neurol       Date:  1991-05       Impact factor: 10.422

8.  Cell cycle regulation of the glyceraldehyde-3-phosphate dehydrogenase/uracil DNA glycosylase gene in normal human cells.

Authors:  N R Mansur; K Meyer-Siegler; J C Wurzer; M A Sirover
Journal:  Nucleic Acids Res       Date:  1993-02-25       Impact factor: 16.971

9.  Tumor necrosis factor alpha-induced glucose transporter (GLUT-1) mRNA stabilization in 3T3-L1 preadipocytes. Regulation by the adenosine-uridine binding factor.

Authors:  J M Stephens; B Z Carter; P H Pekala; J S Malter
Journal:  J Biol Chem       Date:  1992-04-25       Impact factor: 5.157

10.  Expression of facilitative glucose transporter isoforms in human brain tumors.

Authors:  S Nagamatsu; H Sawa; A Wakizaka; T Hoshino
Journal:  J Neurochem       Date:  1993-12       Impact factor: 5.372

View more
  5 in total

Review 1.  Imaging hypoxia in gliomas.

Authors:  I Mendichovszky; A Jackson
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

Review 2.  Glucose transport: meeting the metabolic demands of cancer, and applications in glioblastoma treatment.

Authors:  Collin M Labak; Paul Y Wang; Rishab Arora; Maheedhara R Guda; Swapna Asuthkar; Andrew J Tsung; Kiran K Velpula
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

Review 3.  Central nervous system capillary haemangioblastoma: the pathologist's viewpoint.

Authors:  Mahmoud R Hussein
Journal:  Int J Exp Pathol       Date:  2007-10       Impact factor: 1.925

Review 4.  Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target.

Authors:  Randy L Jensen
Journal:  J Neurooncol       Date:  2009-04-09       Impact factor: 4.130

5.  Blood-brain barrier genomics and cloning of a novel organic anion transporter.

Authors:  Chun Chu; Jian Yi Li; Ruben J Boado; William M Pardridge
Journal:  J Cereb Blood Flow Metab       Date:  2007-08-01       Impact factor: 6.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.